Department of Radiology

Publications

2019

Deidda D, Karakatsanis N, Robson PM, Efthimiou N, Fayad ZA, Aykroyd RG, et al. Effect of PET-MR Inconsistency in the Kernel Image Reconstruction Method. IEEE Trans Radiat Plasma Med Sci. 2019;3(4):400-409.

Chaker S, Al-Dasuqi K, Baradaran H, Demetres M, Delgado D, Nehmeh S, et al. Carotid Plaque Positron Emission Tomography Imaging and Cerebral Ischemic Disease. Stroke. 2019;50(8):2072-2079.

Kim E, Mema E, Axelrod D, Sigmund E, Kim SG, Babb J, et al. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer. Eur J Radiol. 2019;110:163-168.

Jafari R, Sheth S, Spincemaille P, Nguyen TD, Prince MR, Wen Y, et al. Rapid automated liver quantitative susceptibility mapping. J Magn Reson Imaging. 2019;50(3):725-732.

Miyata M, Kakeda S, Toyoshima Y, Ide S, Okada K, Adachi H, et al. Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease. Neuroradiology. 2019;61(11):1251-1259.

Parker DB, Razlighi QR. The Benefit of Slice Timing Correction in Common fMRI Preprocessing Pipelines. Front Neurosci. 2019;13:821.

Seligman L, Kovanlikaya I, Pisapia DJ, Naeger DM, Magge R, Fine HA, et al. Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling. AJR Am J Roentgenol. 2019;212(4):883-891.

Khosla M, Jamison K, Ngo GH, Kuceyeski A, Sabuncu MR. Machine learning in resting-state fMRI analysis. Magn Reson Imaging. 2019;64:101-121.

Amor-Coarasa A, Kelly JM, Singh PK, Ponnala S, Nikolopoulou A, Williams C, et al. [F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4. Molecules. 2019;24(8).

Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, et al. Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. J Nucl Med. 2019;60(12):1794-1801.